Ketamine: Does It Have a Role in Palliative Sedation?

Journal of Pain and Symptom Management

Volumn 36, Issue 4, 2008, Pages

  Carter, Michael J ^a   Gibbins, Jane ^a   Senior Smith, Gaye ^a   Thomas, Steve ^b   Guest, Phillip ^b   Forbes, Karen ^a  

^a BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^b BRISTOL DENTAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT; KETAMINE; LEVOMEPROMAZINE; MIDAZOLAM; OPIATE DERIVATIVE; STEROID; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGITATION; ANAMNESIS; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; FACE PAIN; FEAR; GASTROSTOMY; HALLUCINATION; HUMAN; LETTER; MALE; MEDICAL DECISION MAKING; MONOTHERAPY; NECK DISSECTION; NEUROPATHIC PAIN; PALLIATIVE THERAPY; POSTOPERATIVE PERIOD; PROGNOSIS; SEDATION; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; TONSIL CARCINOMA; TREATMENT FAILURE;

ANALGESICS; FACIAL PAIN; HUMANS; KETAMINE; MALE; PALLIATIVE CARE; TONGUE NEOPLASMS; TREATMENT OUTCOME;

EID: 52049122572     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2008.05.002     Document Type: Letter

References (10)

1. De Graeff A., and Dean M. Palliative sedation therapy in the last weeks of life: a literature review and recommendations for standards. J Palliat Med 10 (2007) 67-85
2. Anon. Prescribing in palliative care. British National Formulary Vol. 53 (2007), BMJ Publishing Group, London
3. Orentlicher D. The Supreme Court and physician-assisted suicide-rejecting assisted suicide but embracing euthanasia. N Engl J Med 337 (1997) 1236-1239
4. Mistraletti G., Donatelli F., and Carli F. Metabolic and endocrine effects of sedative agents. Curr Opin Crit Care 11 (2005) 312-317
5. Berger J.M., Ryan A., Vadivelu N., et al. Ketamine-fentanyl-midazolam infusion for the control of symptoms in terminal life care. Am J Hosp Palliat Care 17 2 (2000) 127-132
6. Okon T. Ketamine: an introduction for the pain and palliative medicine physician. Pain Physician 10 (2007) 493-500
7. Rang H.P., Dale M.M., Ritter J.M., and Moore P. Pharmacology. 5th ed. (2003), Churchill Livingstone, Edinburgh
8. Mercadante S., Arcuri E., Tirelli W., and Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomised, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 4 (2000) 246-251
9. Yang C.Y., Wong C.S., and Chang J.Y. Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Can J Anaesth 43 (1996) 379-383
10. Bell R., Eccleston C., and Kalso E. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 1 (2003) CD003351